Arcturus Therapeutics Holdings Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M |
| Research and development | $112.2M | $195.2M | $192.1M | $147.8M | $173.8M |
| Operating expenses | $158.3M | $248.0M | $245.0M | $193.8M | $215.2M |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M |
| Pretax income | -$65.8M | $81.0M | -$27.9M | $10.6M | -$203.7M |
| Income tax expense | — | -$4,000 | $1.8M | $1.3M | — |
| Net income | -$65.8M | -$80.9M | -$29.7M | $9.3M | -$203.7M |
| Balance Sheet | |||||
| Cash and equivalents | $230.9M | $237.0M | $292.0M | $391.9M | $370.5M |
| Current assets | $241.4M | $306.0M | $386.6M | $403.3M | $379.0M |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M |
| Current liabilities | $36.4M | $65.5M | $82.0M | $127.0M | $99.5M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M |
| Stockholders' equity | $214.0M | $241.0M | $278.5M | $270.3M | $228.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M |
| Depreciation and amortization | $3.0M | $3.5M | $3.0M | $1.5M | $1.2M |
| Stock-based compensation | $25.4M | $38.0M | $34.6M | $30.6M | $28.9M |
| Capital expenditure | $230,000 | $648,000 | $2.9M | $7.7M | $3.4M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 28.4M · Free float 94.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.